SDIX Reports Second Quarter 2010 Results Net Loss Decreases 71%. Progress Made in Life Science Business. Business Wire NEWARK, Del. -- August 04, 2010 SDIX (Nasdaq:SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today reported financial results for the second quarter ended June 30, 2010. Revenues for the quarter ended June 30, 2010 were $6.8 million compared to $6.9 million for the same period in 2009. Year-to-date revenues for the six months ended June 30, 2010 were $13.5 million in 2010, compared to $13.8 million for the same period in 2009. Second Quarter and Recent Highlights *Launched NOVUS BIOLOGICALS and SDIX Partnership – Novus has seen good initial sales from the over 800 pre-made GAT™ Polyclonal Antibodies provided for their catalog. A joint team is collaborating to create additional novel antibodies using GAT to targets selected by Novus for inclusion in their catalog offering. *Wayne P. Yetter joined SDIX’s Board of Directors, effective May 18, 2010 - currently Chief Executive Officer of ProActive for Patients Media, Inc., Mr. Yetter has a 30-year career in the pharmaceutical industry, with executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis. *The RapidChek® SELECT™ Salmonella Enteritidis testing system was commercially launched - applicable to both egg and poultry industries, this product is designed specifically to help U.S. commercial egg producers comply with new FDA regulations that require them to test poultry houses and eggs for Salmonella Enteritidis. Initial orders have been placed, and SDIX has begun shipments while final regulatory validations are underway. *Announced multi-year collaboration with Banyan Biomarkers related to biomarker discovery work in the detection of traumatic brain injury – SDIX will provide antibody production from Banyan’s novel set of cell lines and will collaborate with them to utilize our complete range of immunosolutions in the development of additional biomolecules for this critical research. Mr. Francis DiNuzzo, the Company’s President and CEO, said, “Our results for the second quarter of 2010, though not demonstrating increased revenue year over year, continue to show improvement in our operating model and the impact of our strategic focus on Life Science and Food Safety. A significant portion of our efforts and resources are now focused on driving growth in our target markets. We are seeing the benefits with improved performance in Life Science, and while Food Safety revenue was down year over year, we believe that the outlook for the remainder of the year indicates an improving picture. We recently launched a new testing system that will help U.S. commercial egg producers implement the FDA-mandated testing for Salmonella Enteritidis. We are also collaborating with Banyan Biomarkers in their biomarker work for traumatic brain injury detection. These new developments exemplify the inroads we are making in our target markets.” Financials Gross profit (defined as total revenues less manufacturing expenses) for the quarter ended June 30, 2010 was $4.0 million, as compared to $3.6 million for the same period in 2009. Year-to-date gross profit was $8.0 million in 2010, compared to $7.4 million for 2009. Gross margins were 59% for the second quarter of 2010, compared to 53% for the same period in 2009. Gross margins for the six months ended June 30, 2010 were 59% compared to 54% for the same period in 2009. Operating loss for the second quarter decreased 72% to $201,000 from $714,000 in the second quarter of 2009. Operating loss for the first six months of 2010 fell 50% to $648,000 from $1.3 million for the first six months of 2009. Net loss for the second quarter of 2010 fell 71% to $215,000, or $0.01 per diluted share, compared to a net loss of $734,000, or $0.04 per diluted share, for the same period in 2009. For the six month period ended June 30, 2010, the net loss was $674,000, or $0.03 per diluted share, compared to a net loss of $1.3 million, or $0.06 per diluted share, for the same period in 2009. Life Science Revenues Life Science revenues were $3.7 million for the quarter ended June 30, 2010, a 10% increase from $3.3 million for the same period in 2009. For the six months ended June 30, 2010, Life Science revenues increased 6% to $7.5 million compared to $7.0 million for the same period in 2009. Kit Revenues Kit revenues were $3.1 million, including contract revenues of $75,000, for the second quarter ended June 30, 2010, reflecting a decrease of 13%, from $3.5 million in the second quarter of 2009. For the six months ended June 30, 2010, kit revenues decreased 10% to $6.0 million compared to $6.6 million for the same period in 2009. The decrease in kit sales was primarily attributable to lower revenues in the Water Quality and Ag-GMO markets where SDIX has been reducing its focus. Quarter Ended June 30, 2010 2009 Life Sciences $ 3.7 million $ 3.3 million Food Pathogen Products $ 1.3 million $ 1.4 million Ag-GMO Products, including contract $ 0.5 million $ 0.6 million revenue Water and Environmental Products $ 1.3 million $ 1.5 million Conference Call The dial-in number for our live conference call, to be held at 4:30 p.m. ET on August 4, 2010, is 877-407-9210 (201-689-8049 outside the U.S.). A live webcast of the conference call will be available on the Company’s website, www.sdix.com, as well as www.investorcalendar.com. For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on August 4, 2010 through 11:59 p.m. ET on August 19, 2010. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 354464. About SDIX (www.sdix.com) SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the Pharmaceutical, biotechnology, diagnostics, and food safety markets. For nearly 20 years, SDIX has developed antibodies which advance its customers’ immuno-based work – reducing time, labor, and costs while increasing accuracy and reliability of results. SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis. This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission. STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Six Months Ended June 30, Ended June 30, 2010 2009 2010 2009 Revenues $ 6,796 $ 6,853 $ 13,487 $ 13,755 OPERATING EXPENSES: Manufacturing 2,764 3,223 5,519 6,320 Research and 764 820 1,440 1,483 development Selling, general and 3,469 3,524 7,184 7,244 administrative Gain on disposal of - - (8 ) - assets Total operating 6,997 7,567 14,135 15,047 expenses Operating loss (201 ) (714 ) (648 ) (1,292 ) Interest income (14 ) - (26 ) 5 (expense), net Loss before (215 ) (714 ) (674 ) (1,287 ) taxes Income tax expense - 20 - 8 (benefit) Net loss (215 ) (734 ) (674 ) (1,295 ) Basic loss per $ (0.01 ) $ (0.04 ) $ (0.03 ) $ (0.06 ) share Shares used in computing 20,229,963 20,105,814 20,209,158 20,070,882 basic loss per share Diluted loss $ (0.01 ) $ (0.00 ) $ (0.03 ) $ (0.06 ) per share Shares used in computing 20,229,963 20,105,814 20,209,158 20,070,882 diluted loss per share STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited) June 30, December 31, 2010 2009 ASSETS Current Assets : Cash and cash equivalents $ 7,650 $ 7,937 Restricted cash 1,250 1,250 Receivables, net 3,907 3,650 Inventories 3,658 3,714 Deferred tax asset 1 1 Other current assets 761 551 Total current assets 17,227 17,103 Property and equipment, net 4,307 4,626 Other assets 85 10 Deferred tax asset 51 51 Intangible assets, net 1,378 1,435 Total assets $ 23,048 $ 23,225 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities : Current portion of long-term debt $ 400 $ 400 Accounts payable 449 571 Accrued expenses 1,978 1,386 Deferred revenue 2 75 Total current liabilities 2,829 2,432 Long-term debt 500 700 Stockholders' Equity: Preferred stock, $.01 par value, 20,920,648 shares authorized, no shares issued or - - outstanding Common stock, $.01 par value, 35,000,000 shares authorized, 20,902,030 and 20,786,515 issued at 209 208 June 30, 2010 and December 31, 2009, respectively Additional paid-in capital 41,294 40,958 Treasury stock, 406,627 common shares at cost at (555 ) (555 ) June 30, 2010 and December 31, 2009 Accumulated deficit (20,950 ) (20,276 ) Cumulative translation adjustments (279 ) (242 ) Total stockholders' equity 19,719 20,093 Total liabilities and stockholders' equity $ 23,048 $ 23,225 Contact: SDIX Kevin Bratton VP and CFO 302-456-6789 email@example.com
SDIX Reports Second Quarter 2010 Results
Press spacebar to pause and continue. Press esc to stop.